Is Pfizer Putting the Car-T Before the Horse?
Pfizer has moved to establish a good preclinical presence in a promising emerging cancer therapy class
Is Gene Therapy Medicine's Next Big Thing?
Bluebird Bio (BLUE) is advancing gene therapies through clinic using technology that Celgene (CELG) thinks could someday be used to treat cancer.
Dendreon's CEO Exits: Is this the Beginning of the End?
Dendreon CEO John Johnson announced yesterday that he is stepping down for "personal reasons." His departure comes ahead of a large company debt payment. Could Dendreon be on the precipice of bankruptcy?
Tuesday’s Top Biotech Stories: Achillion, Receptos, and Dendreon
Achillion, Receptos, and Dendreon could all make waves in biotech headlines this Tuesday morning.